Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease

Evans, Allan M.; Faull, Randall J.; Nation, Roger L.; Prasad, Shilpanjali; Elias, Tony J; Reuter, Stephanie E; Fornasini, Gianfranco

doi:10.1111/j.1523-1755.2004.00916.x

Cited by 64 publications

(91 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,15,17,18 Recent research by our group has investigated the relationship between the duration of haemodialysis treatment (dialysis age) and carnitine status. 21 The study demonstrated a signi¢cant negative correlation between plasma L-carnitine concentrations and dialysis age, with the majority of the reduction in L-carnitine concentrations occurring within the ¢rst few months of haemodialysis treatment. The decline in plasma L-carnitine with increasing dialysis age was accompanied by a similar reduction in plasma acetyl-L-carnitine concentrations (acetyl-L-carnitine is the most abundant acylcarnitine in the body); however, acetyl-L-carnitine concentrations remained above the reference range for healthy individuals.…”

Section: Introductionmentioning

confidence: 97%

Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease

et al. 2005

Self Cite

View full text Add to dashboard Cite

Background Patients with end-stage renal disease (ESRD) undergoing long-term haemodialysis exhibit low L-carnitine and elevated acylcarnitine concentrations. This study evaluated endogenous concentrations of an array of acylcarnitines (carbon chain length up to 18) in healthy individuals and ESRD patients receiving haemodialysis, and examined the impact of a single haemodialysis session on acylcarnitine concentrations.

show abstract

Section: Introductionmentioning

confidence: 97%

Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease

et al. 2005

Self Cite

View full text Add to dashboard Cite

show abstract

“…In incident hemodialysis (HD) patients, the plasma carnitine level decreases within the first week of the treatment, with a continual decrease over the first 12 months of treatment [4]. The carnitine content of the skeletal muscle also decreases in hemodialysis patients and is inversely correlated with time on HD [4,5].…”

Section: Introductionmentioning

confidence: 99%

Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study

et al. 2015

View full text Add to dashboard Cite

Background: L-carnitine is an essential compound that facilitates the transport of long-chain fatty acid across the inner mitochondrial membrane for β-oxidation. However, the effect of L-carnitine supplementation remains to be fully explored in patients with chronic kidney disease. We aimed in this study to determine the multidirectional effects of L-carnitine supplementation on clinical parameters in more detail. Methods: We orally administered L-carnitine to maintain serum-free carnitine levels within the normal range (30 to 70 μmol/L) for 6 months in 21 hemodialysis (HD) patients (age, 74 ± 11 years; time on HD, 60 ± 84 months).

show abstract

“…Repeated dialysis treatment over an extended period results in a deficiency of tissue carnitine. 9 Carnitine insufficiency in patients on long-term HD affects dialysis-related symptoms such as skeletal myopathy, cardiomyopathy, poor exercise performance, anemia, and dialytic complications, such as hypotension, cramps, weakness, and fatigue, 10,11 which decrease dialysis tolerance and reduce the long-term survival rate. Consequently, carnitine therapy has been used and extensively studied in patients with ESRD.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of different carnitine levels for improving the prognosis of patients undergoing hemodialysis

Zhang

et al. 2016

Renal Failure

View full text Add to dashboard Cite

Objective: To investigate plasma-free carnitine (Fc), acylcarnitine (Ac), and total carnitine (Tc) levels in patients undergoing hemodialysis (HD), and to explore their clinical significance. Methods: A total of 20 subjects were in the normal control group and 133 patients undergoing HD were divided into medicated (received carnitine treatment) and non-medicated groups. The medicated group was further divided into three subgroups according to Fc level: , and ! 300 lmol/L. We used non-derivative tandem mass spectrometry to determine carnitine levels, and clinical symptoms such as weakness, hypotension, and muscle cramps were recorded during dialysis. Results: Fc and Tc levels were significantly lower in the non-medicated group than in the control group, whereas Fc, Ac, and Tc levels were higher in the medicated than non-medicated group (p< .05). The medicated group had fewer symptoms during dialysis than the non-medicated group such as weakness, hypotension, and muscle cramps (p< .05). An additional comparison showed that the incidence rates of hypotension and muscle cramps in the Fc < 80-199 lmol/L group were significantly lower than those in the Fc ! 300 lmol/L medicated and non-medicated groups. Conclusions: Patients undergoing HD have low carnitine levels. L-Carnitine can effectively increase Fc concentration and improve clinical symptoms; however, only the proper Fc range can reduce complications caused by dialysis. Thus, this range needs to be determined. ARTICLE HISTORY

show abstract

Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease

Cited by 64 publications

References 29 publications

Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease

Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease

Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study

Clinical significance of different carnitine levels for improving the prognosis of patients undergoing hemodialysis

Contact Info

Product

Resources

About